Business
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"\n \n YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year\n \n 1\n \n , and achieved record brand profitability\n \n \n Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026\n \n \n Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025\n \n \n TRELEGY year-to-date sales on track to achieve $50 million milestone in 2025\n \n 2\n \n \n \n Strong balance sheet with $333 million in cash and no debt\n \n \n \n DUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025.\n \n \n \n \n \n \n \n \"Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven, underscoring our commitment to financial and operational discipline,\" said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. \"In parallel, we continue to advance ampreloxetine toward topline results from the pivotal Phase 3 CYPRESS study in the first quarter of 2026. Backed by a strong balance sheet, durable YUPELRI cash flow, and multiple high-value milestones ahead, we approach this important catalyst from a position of strength—ready to deliver results that could transform the standard of care for multiple system atrophy patients and drive lasting value for patients and shareholders.\" \n \n Operational Highlights:\n \n \n YUPELRI\n ® (revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD):\n \n Achieved all-time high U.S. net sales of $71.4 million in Q3 2025, increasing 15% year-over-year (YoY) (Q3 2025 vs Q3 2024)1 driven by customer demand growth of 6% YoY (Q3 2025 vs Q3 2024)3 and improved net pricing due to favorable channel mix.\n Approximately $54 million required in Q4 2025 to trigger $25 million milestone for the achievement of $250 million of net sales in 2025.4\n Increased doses pulled through the hospital channel by 29% YoY (Q3 2025 vs Q3 2024), reflecting anot...